EAU 2018

EAU 2018: Acute Obstructive Pyelonephritis Can Be Caused By E. coli at ≤104 Bacteriuria Level Experimental Model

Copenhagen, Denmark (UroToday.com) Bacteria in the urine, or bacteruria, can be symptomatic or asymptomatic in patients. In patients where it is symptomatic, it may cause development of upper urinary tract infections which can lead to acute obstructive pyelonephritis (AOP). Dr. M.I. Kogan the team sought to determine the rate of AOP in an animal experimental model.

EAU 2018: The Impact of Acute Kidney Injury on Prognosis in Patients With Urological Sepsis

Copenhagen, Denmark (UroToday.com) Acute kidney injury (AKI) is common in patients who have undergone urological procedures. AKI is increasing in incidence and is associated with longer hospitals stays for patients as well as considerable morbidity and mortality. Although common not much is known about the effect of AKI in patients with urological sepsis.

EAU 2018: PCNL SIRS Risk Increasing in Patients with Positive Stone Culture and Sub-optimal Renal Drainage

Copenhagen, Denmark (UroToday.com) Dr. S Bolomytis presented data that determined which preoperative risk factors and postoperative outcomes were associated with PCNL SIRS. As an introduction to his talk, Dr. Bolomytis stated the gold standard for the treatment and management of large renal stones is percutaneous nephrolithotomy. However, one of the most complications related to this procedure is systemic inflammatory response syndrome (SIRS).

EAU 2018: What You Could Miss at Follow-Up After Radical Cystectomy for Muscle Invasive Bladder Cancer

Copenhagen, Denmark (UroToday.com)  Dr. Veskimae from Finland provided a discussion regarding the follow-up of patients after radical cystectomy for muscle invasive bladder cancer (MICB) with specific at-risk time points for oncologic and non-oncologic issues. 

EAU 2018: What Will We Recommend in 2025 for the Management of Bladder Cancer?

Copenhagen, Denmark (UroToday.com) Dr. Todenhofer from Germany discussed how the recommendations and treatment options may change in 2025 compared to present day for patients with bladder cancer. Dr. Todenhofer started by noting that after several decades of static treatment recommendations/no improvement for bladder cancer patients, movement is occurring the field. Specific to the EAU guidelines for metastatic disease:

EAU 2018: How to Interpret the Specimen’s Pathology – Radical Cystectomy for Muscle Invasive Bladder Cancer

Copenhagen, Denmark (UroToday.com) Dr. Arndt Hartmann, a pathologist from Germany, provided the pathologist’s perspective when assessing bladder cancer specimens. Dr. Hartmann started by highlighting the EAU guidelines recommendations for assessment of tumor specimens, specifically that (i) there should be record of depth of tumor invasion, (ii) record of margins with special attention paid to the radial margin, prostate, ureter, urethral and peritoneal fat, uterus, and vagina, (iii) record of the number of lymph nodes, the number of positive lymph nodes, and extranodal spread, (iv) record of the lymphatic or blood vessel invasion and extranodal extension, and (v) record of the presence of CIS. Dr. Hartmann notes that in MIBC, all cases are high-grade urothelial carcinoma and that for this reason, no prognostic information can be provided by grading MIBC. 

EAU 2018: Morbidity Evaluation of Antiplatelet and Anticoagulant Treatments According to Their Perioperative Management During Photovaporisation of the Prostate by Greenlight Laser

Copenhagen, Denmark (UroToday.com)  Dr. B. Pradere, clinical urologist from the CHU Tours in Tours, France, shared his findings on the feasibility of photovaporizaiton of the prostate (PVP) by Greenlight laser  for patients who are unable to undergo surgery without taking antiplatelet (AP) or anticoagulant (AC) medications.